

Type 2 Diabetes Prevention: An Opportunity for a New Discipline

Tom A. Elasy, MD, MPH, Editor-in-Chief

In this issue of *Clinical Diabetes*, Leena A. Ahmad, MD, and Jill P. Crandall, MD, provide a comprehensive review of the data on type 2 diabetes prevention (p. 53). One cannot help but notice the magnitude of benefit (a reduction of anywhere from 25 to 60%) of a variety of modalities (e.g., lifestyle, medication, and surgery) for those who are at high risk (traditionally those with impaired glucose

tolerance) for developing type 2 diabetes. It is difficult to think of many chronic diseases for which the evidence base for prevention is so robust and the magnitude of benefit so large.

Although the benefits of efforts to prevent or delay type 2 diabetes have been known for nearly a decade, the incidence and prevalence of diabetes continue to rise. Explanations and attempts to bridge the gap between

what we know and what we do usually fall under the purview of translational research. Specifically, individuals in this field are charged with generating and testing hypotheses about the “how” of moving care to where we ought to be in light of what we know. The issue is less “What is the right thing to do?” and more “How can we best accomplish what we know we need to do?”

Clinical Diabetes

Editor
Tom A. Elasy, MD, MPH

Associate Editors
Michael J. Fowler, MD
Martha M. Funnell, MS, RN, CDE
Davida F. Kruger, MSN, APRN-BC, BC-ADM
Michael Pignone, MD, MPH
Russell L. Rothman, MD, MPP
Mark E. Splaine, MD, MS

Advertising Representatives

Pharmaceutical/Medical Accounts
B. Joseph Jackson, President; Paul Nalbandian, Vice President, Business Development; Charles Novak, Vice President, Sales; The Jackson Gaeta Group, Inc., 33 Smull Avenue, Caldwell, NJ 07006, (973) 403-7677

Editorial Board
Arti Bhan, MD
Larry Deeb, MD
Elizabeth Nardacci, MS, FNP-C, CDE, BC-ADM
Patrick O'Connor, MD, MPH
Heather Remtema, MPH, RD, CCRP
Christopher Saudek, MD
Neil Skolnik, MD
John White, PA, PharmD
Carol Wysham, MD

Vice President, Publications
Martha Ramsey

Director, Scholarly Journals
Christian S. Kohler

Manager, Periodicals Production
Keang Hok

Managing Editor
Debbie Kendall

Associate Publisher
Howard Richman

Advertising Production Specialist
Julie DeVoss

Director, Membership/Subscription Services
James Skowrenski

Manager, Membership/Subscription Services
Jeremy N. Baird

Associate Director, Billing & Collections
Laurie Ann Hall



Audit Bureau
of Circulations

American Diabetes Association Officers

Chair of the Board
Nash M. Childs, PE

President, Medicine & Science
Richard M. Bergenstal, MD

President, Health Care & Education
Christine T. Tobin, RN, MBA, CDE

Secretary/Treasurer
Gerard B. Nee, CPA

Chair of the Board-Elect
John W. Griffin, Jr.

President-Elect, Medicine & Science
Robert R. Henry, MD

President-Elect, Health Care & Education
Elizabeth Mayer-Davis, MSPH, PhD, RD

Secretary/Treasurer-Elect
Dwight Holing

Vice Chair of the Board
L. Hunter Limbaugh, JD

Vice President, Medicine & Science
Vivian Fonesca, MD

Vice President, Health Care & Education
Geraldyn Spollett, MSN, APN, CDE

Vice Secretary/Treasurer
Pearson C. Cummin, III

Chief Executive Officer
Larry Hausner

Clinical Diabetes

A PUBLICATION OF THE AMERICAN DIABETES ASSOCIATION®, INC. TM

Clinical Diabetes Mission Statement

The mission of *Clinical Diabetes* is to provide primary care providers and all clinicians involved in the care of people with diabetes with information on advances and state-of-the-art care for people with diabetes. *Clinical Diabetes* is also a forum for discussing diabetes-related problems in practice, medical-legal issues, case studies, digests of recent research, and patient education materials.

ADA Mission Statement

The mission of the American Diabetes Association is to prevent and cure diabetes and to improve the lives of all people affected by diabetes.

Clinical Diabetes (Print ISSN 0891-8929, Online ISSN 1945-4953) is published quarterly by the American Diabetes Association®, Inc., 1701 N. Beauregard St., Alexandria, VA 22311. Single issue rates are \$45 in the U.S., \$65 in Canada and Mexico (for Canada GST included), and \$75 in all other countries. Periodical postage paid at Alexandria, VA, and additional mailing offices. For subscription information, call toll free (800) 232-3472, 8:30 a.m. to 5:00 p.m. EST, Monday through Friday. Outside the U.S., call (703) 549-1500.

Claims for missing issues must be made within 6 months of publication. The publisher expects to supply missing issues free of charge only when losses have been sustained in transit and when the reserve stock permits.

Postmaster: Send change of address to *Clinical Diabetes* COA, 1701 N. Beauregard St., Alexandria, VA 22311-1717.

©American Diabetes Association®, Inc., 2010.
Printed in the USA.

Opinions expressed in signed articles are those of the authors and are not necessarily endorsed by the American Diabetes Association.

Many efforts have tried to bridge this gap: Teach new learners evidence-based medicine. Equip physicians to communicate better. Start disease management companies. Design and distribute better information technology. Do community-based participatory research. Increase funding for translational research that includes sustainability and scalability.

Many of these efforts have had some success. But that success has been limited, largely because these efforts rarely grasp the levers of change, and even when they are grasped, the grip is not sufficiently strong to effect change.

I believe that our efforts need two fundamental changes. First, we need to develop a new specialty of individuals whose expertise is in Implementation Science. These indi-

viduals would draw attributes from several disciplines and focus more on the intersection of policy and practice. There is too much fragmentation of efforts and talents.

Such experts would understand complexity science, principles of industrial engineering, knowledge management, and participatory methods and would also be grounded in the business of health care. We have too many individuals trying to translate knowledge whose skill sets are too narrow for the task at hand. Although good leaders are good at assembling talents that match the task at hand, these leaders should at least be conversant with the tasks themselves. We have too few individuals.

Second, we need efforts more potent than a Red Ryder BB gun. These efforts should involve large-

scale collaborations that appreciate the complexity of the problem of translation. Few of these efforts will be randomized, controlled trials. We simply cannot continue to randomize a couple of hundred people to test one specific effect on one specific outcome if our goal is to translate knowledge and implement sustainable, scalable improvement. Although this is a clean and crisp approach, it is weak.

Type 2 diabetes can be delayed and possibly prevented. We should continue our efforts to prevent this disease. Our efforts will be accelerated and amplified if we use this problem as an opportunity to develop a new specialty in Implementation Science whose practitioners will employ appropriately potent and comprehensive efforts.